Induction of Tumor-Immune Responses and Their Interaction with the Developing Tumor

Baldwin, Robert; Robins, R. A.

doi:10.1007/978-1-4684-2841-4_6

Cited by 17 publications

(4 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These antibody-producing B cells could act in concert along with cytotoxic T cells specific for the tumor antigen and induce cytotoxicity, potentially retarding tumor growth. The antibodies could trigger complement-mediated cytotoxicity [180] or antibody-dependent cell-mediated cytotoxicity [181]. Furthermore, the antibodies may bind to their target and interfere with the function of the antigen.…”

Section: Potential Clinical Applications Of Sclc-related Autoantibodimentioning

confidence: 99%

Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy

Kazarian

Laird-Offringa

2011

Mol Cancer

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) is the most aggressive lung cancer subtype and lacks effective early detection methods and therapies. A number of rare paraneoplastic neurologic autoimmune diseases are strongly associated with SCLC. Most patients with such paraneoplastic syndromes harbor high titers of antibodies against neuronal proteins that are abnormally expressed in SCLC tumors. These autoantibodies may cross-react with the nervous system, possibly contributing to autoimmune disease development. Importantly, similar antibodies are present in many SCLC patients without autoimmune disease, albeit at lower titers. The timing of autoantibody development relative to cancer and the nature of the immune trigger remain to be elucidated. Here we review what is currently known about SCLC-associated autoantibodies, and describe a recently developed mouse model system of SCLC that appears to lend itself well to the study of the SCLC-associated immune response. We also discuss potential clinical applications for these autoantibodies, such as SCLC diagnosis, early detection, and therapy.

show abstract

Section: Potential Clinical Applications Of Sclc-related Autoantibodimentioning

confidence: 99%

Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy

Kazarian

Laird-Offringa

2011

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…Bound NANA in blood could be removed by the reticuloendothelial system (Baldwin & Robins;1977) or by specific antibodies (Kim, 1979). Thus one has to be cautious in interpreting in vivo results, such as in the R3230AC tumour model where bound NANA levels were low at early stages of growth.…”

Section: Resultsmentioning

confidence: 99%

Analysis of mammary tumour cell metastasis and release of bound n-acetylneuraminic acid

Hoon¹,

Ng²,

Ramshaw³

1985

Br J Cancer

View full text Add to dashboard Cite

Summary A tumour model consisting of the highly metastatic mammary 13762 parental line, the nonmetastatic and 6-thioguanine-resistant (TgR) variant line, and two TgR revertant lines (TgRrev, TgRrevM) that were occasionally metastatic, were used to determine whether the relase of N-acetylneuraminic acid (NANA) was related to tumour metastasis. For comparative purposes, the occasionally metastatic R3230AC and the nonmetastatic DMBA8 tumour lines were studied. The NANA was considered to be in bound form, because acid hydrolysis was required to release it for high-pressure liquid chromatographic analyses. Sera of animals bearing the 13762 and R3230AC tumours had high levels of bound NANA. No differences were found in serum NANA levels in animals bearing metastatic or non-metastatic R3230AC tumours. Low levels of bound NANA were found in animals bearing the other tumour lines regardless of whether metastasis occurred or not. The experiments in vitro substantiated the in vivo findings. The phenotypic expression of bound NANA shedding did not correlate well with metastatic potential of the mammary tumour line. Our analyses suggest that this phenotypic marker cannot be used as a reliable indicator of metastasis.

show abstract

“…Finally, these results touch on a controversy of many years' standing. The classical concept of tumor enhancement involved blocking of the immune response by serum factors that at first seemed to be antibody and later were believed to be complexes of tumor antigen and its antibody (Baldwin andRobins, 1977, Sjogren et al, 1971). Suppressor T cells, on the other hand, appeared to present a contradictory mechanism by which tumors can escape from host surveillance.…”

Section: Discussionmentioning

confidence: 99%

Tumor enhancing T lymphocytes in mice: Further studies on characteristics and mechanism of activity

Small

1982

Intl Journal of Cancer

View full text Add to dashboard Cite

In order to test the possibility that tumor-enhancing T lymphocytes can suppress other lymphoid cells, such as those with anti-tumor activity, their effect was tested in an allogeneic response of cell-mediated lysis. Normal thymocytes and spleen cells from mice with advanced tumors, two populations which enhance the growth of solid tumors, both suppressed the generation of CML. Since these results suggest that the mechanism of enhancement by T cells may resemble suppression in other immune responses, we looked for Fc receptors on the sensitized cells involved in tumor enhancement. Cells expressing Fc receptors appeared to be necessary for enhancement of tumor growth to occur.

show abstract

Induction of Tumor-Immune Responses and Their Interaction with the Developing Tumor

Cited by 17 publications

References 108 publications

Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy

Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy

Analysis of mammary tumour cell metastasis and release of bound n-acetylneuraminic acid

Tumor enhancing T lymphocytes in mice: Further studies on characteristics and mechanism of activity

Contact Info

Product

Resources

About